We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
U.S. drug industry representatives are applauding the approval of strict new patent rules in India, but the action has been met with mixed reactions elsewhere, including from international advocacy groups and within India’s own drug industry.
The pharmaceutical industry is not doing enough to convey a clear, consistent message to the public, according to the new head of PhRMA, who has vowed to do nothing less than “rescue and restore” the industry’s reputation.
Retiring congressman Rep. Billy Tauzin (R-La.) stepped into the lead role at PhRMA this month, taking over as the trade industry association’s president and CEO.
Spending on brand drugs accounts for only 7 cents out of every healthcare dollar, according to a new PhRMA website that explains the drug development process and answers critics of the drug industry.
Only 7 cents out of every healthcare dollar is spent on brand drugs, according to a new PhRMA website that provides detailed information on the drug development process and answers critics of the pharmaceutical industry.
Biotechnology and pharmaceutical firms have hundreds of biotech products under development to treat roughly 150 diseases — all new products that are either in human clinical trials or under review by the FDA, according to a new survey by PhRMA.